Jennifer H Jordan1, Sujethra Vasu1, Timothy M Morgan1, Ralph B D'Agostino1, Giselle C Meléndez1, Craig A Hamilton1, Andrew E Arai1, Songtao Liu1, Chia-Ying Liu1, João A C Lima1, David A Bluemke1, Gregory L Burke1, W Gregory Hundley2. 1. From the Department of Internal Medicine, Section on Cardiovascular Medicine (J.H.J., S.V., G.C.M., W.G.H.), Department of Public Health Sciences (T.M.M., R.B.D., G.L.B.), Department of Pathology, Section on Comparative Medicine (G.C.M.), Department of Biomedical Engineering (C.A.H.), and Department of Radiological Sciences (W.G.H.), Wake Forest School of Medicine, Winston-Salem, NC; National Heart, Lung and Blood Institute (A.E.A.), Radiology and Imaging Sciences (S.L.), National Institutes of Health, Bethesda, MD; and Department of Radiology, Johns Hopkins University, Baltimore, MD (C.-Y.L., J.A.C.L., D.A.B.). 2. From the Department of Internal Medicine, Section on Cardiovascular Medicine (J.H.J., S.V., G.C.M., W.G.H.), Department of Public Health Sciences (T.M.M., R.B.D., G.L.B.), Department of Pathology, Section on Comparative Medicine (G.C.M.), Department of Biomedical Engineering (C.A.H.), and Department of Radiological Sciences (W.G.H.), Wake Forest School of Medicine, Winston-Salem, NC; National Heart, Lung and Blood Institute (A.E.A.), Radiology and Imaging Sciences (S.L.), National Institutes of Health, Bethesda, MD; and Department of Radiology, Johns Hopkins University, Baltimore, MD (C.-Y.L., J.A.C.L., D.A.B.). ghundley@wakehealth.edu.
Abstract
BACKGROUND: Cardiovascular magnetic resonance T1 mapping characteristics are elevated in adult cancer survivors; however, it remains unknown whether these elevations are related to age or presence of coincident cardiovascular comorbidities. METHODS AND RESULTS: We performed blinded cardiovascular magnetic resonance analyses of left ventricular T1 and extracellular volume (ECV) fraction in 327 individuals (65% women, aged 64±12 years). Thirty-seven individuals had breast cancer or a hematologic malignancy but had not yet initiated their treatment, and 54 cancer survivors who received either anthracycline-based (n=37) or nonanthracycline-based (n=17) chemotherapy 2.8±1.3 years earlier were compared with 236 cancer-free participants. Multivariable analyses were performed to determine the association between T1/ECV measures and variables associated with myocardial fibrosis. Age-adjusted native T1 was elevated pre- (1058±7 ms) and post- (1040±7 ms) receipt of anthracycline chemotherapy versus comparators (965±3 ms; P<0.0001 for both). Age-adjusted ECV, a marker of myocardial fibrosis, was elevated in anthracycline-treated cancer participants (30.4±0.7%) compared with either pretreatment cancer (27.8±0.7%; P<0.01) or cancer-free comparators (26.9±0.2%; P<0.0001). T1 and ECV of nonanthracycline survivors were no different than pretreatment survivors (P=0.17 and P=0.16, respectively). Native T1 and ECV remained elevated in cancer survivors after accounting for demographics (including age), myocardial fibrosis risk factors, and left ventricular ejection fraction or myocardial mass index (P<0.0001 for all). CONCLUSIONS: Three years after anthracycline-based chemotherapy, elevations in myocardial T1 and ECV occur independent of underlying cancer or cardiovascular comorbidities, suggesting that imaging biomarkers of interstitial fibrosis in cancer survivors are related to prior receipt of a potentially cardiotoxic cancer treatment regimen.
BACKGROUND: Cardiovascular magnetic resonance T1 mapping characteristics are elevated in adult cancer survivors; however, it remains unknown whether these elevations are related to age or presence of coincident cardiovascular comorbidities. METHODS AND RESULTS: We performed blinded cardiovascular magnetic resonance analyses of left ventricular T1 and extracellular volume (ECV) fraction in 327 individuals (65% women, aged 64±12 years). Thirty-seven individuals had breast cancer or a hematologic malignancy but had not yet initiated their treatment, and 54 cancer survivors who received either anthracycline-based (n=37) or nonanthracycline-based (n=17) chemotherapy 2.8±1.3 years earlier were compared with 236 cancer-free participants. Multivariable analyses were performed to determine the association between T1/ECV measures and variables associated with myocardial fibrosis. Age-adjusted native T1 was elevated pre- (1058±7 ms) and post- (1040±7 ms) receipt of anthracycline chemotherapy versus comparators (965±3 ms; P<0.0001 for both). Age-adjusted ECV, a marker of myocardial fibrosis, was elevated in anthracycline-treated cancerparticipants (30.4±0.7%) compared with either pretreatment cancer (27.8±0.7%; P<0.01) or cancer-free comparators (26.9±0.2%; P<0.0001). T1 and ECV of nonanthracycline survivors were no different than pretreatment survivors (P=0.17 and P=0.16, respectively). Native T1 and ECV remained elevated in cancer survivors after accounting for demographics (including age), myocardial fibrosis risk factors, and left ventricular ejection fraction or myocardial mass index (P<0.0001 for all). CONCLUSIONS: Three years after anthracycline-based chemotherapy, elevations in myocardial T1 and ECV occur independent of underlying cancer or cardiovascular comorbidities, suggesting that imaging biomarkers of interstitial fibrosis in cancer survivors are related to prior receipt of a potentially cardiotoxic cancer treatment regimen.
Authors: Martin Ugander; Abiola J Oki; Li-Yueh Hsu; Peter Kellman; Andreas Greiser; Anthony H Aletras; Christopher T Sibley; Marcus Y Chen; W Patricia Bandettini; Andrew E Arai Journal: Eur Heart J Date: 2012-01-24 Impact factor: 29.983
Authors: Gregory T Armstrong; Juan Carlos Plana; Nan Zhang; Deokumar Srivastava; Daniel M Green; Kirsten K Ness; F Daniel Donovan; Monika L Metzger; Alejandro Arevalo; Jean-Bernard Durand; Vijaya Joshi; Melissa M Hudson; Leslie L Robison; Scott D Flamm Journal: J Clin Oncol Date: 2012-07-16 Impact factor: 44.544
Authors: Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke Journal: AJR Am J Roentgenol Date: 2006-06 Impact factor: 3.959
Authors: Tomas G Neilan; Otavio R Coelho-Filho; Diego Pena-Herrera; Ravi V Shah; Michael Jerosch-Herold; Sanjeev A Francis; Javid Moslehi; Raymond Y Kwong Journal: Am J Cardiol Date: 2012-08-21 Impact factor: 2.778
Authors: Darius Dabir; Nicholas Child; Ashwin Kalra; Toby Rogers; Rolf Gebker; Andrew Jabbour; Sven Plein; Chung-Yao Yu; James Otton; Ananth Kidambi; Adam McDiarmid; David Broadbent; David M Higgins; Bernhard Schnackenburg; Lucy Foote; Ciara Cummins; Eike Nagel; Valentina O Puntmann Journal: J Cardiovasc Magn Reson Date: 2014-10-21 Impact factor: 5.364
Authors: Seyyed M R Kazemi-Bajestani; Harald Becher; Konrad Fassbender; Quincy Chu; Vickie E Baracos Journal: J Cachexia Sarcopenia Muscle Date: 2014-03-14 Impact factor: 12.910
Authors: Srilakshmi Vallabhaneni; Kathleen W Zhang; Jose A Alvarez-Cardona; Joshua D Mitchell; Henning Steen; Pamela K Woodard; Daniel J Lenihan Journal: Int J Cardiovasc Imaging Date: 2021-05-12 Impact factor: 2.357
Authors: Gregory J Cascino; Woo Bin Voss; Jonathan Canaani; Nicholas Furiasse; Alfred Rademaker; Bonnie Ky; Selina Luger; Jessica K Altman; James M Foran; Mark R Litzow; Martin S Tallman; Vera Rigolin; Nausheen Akhter Journal: Echocardiography Date: 2019-11-08 Impact factor: 1.724
Authors: Thiago Ferreira de Souza; Thiago Quinaglia A C Silva; Felipe Osorio Costa; Ravi Shah; Tomas G Neilan; Lício Velloso; Wilson Nadruz; Fabricio Brenelli; Andrei Carvalho Sposito; Jose Roberto Matos-Souza; Fernando Cendes; Otávio Rizzi Coelho; Michael Jerosch-Herold; Otavio Rizzi Coelho-Filho Journal: JACC Cardiovasc Imaging Date: 2018-08
Authors: Giselle C Meléndez; Bunyapon Sukpraphrute; Ralph B D'Agostino; Jennifer H Jordan; Heidi D Klepin; Leslie Ellis; Zanetta Lamar; Sujethra Vasu; Glenn Lesser; Gregory L Burke; Kathryn E Weaver; William O Ntim; W Gregory Hundley Journal: Am J Cardiol Date: 2017-03-22 Impact factor: 2.778